Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial - 05/08/11
Résumé |
Background |
ST-elevation myocardial infarction (STEMI) patients with a prior MI history have worse outcomes. The prognostic significance of silent MI (pathologic Q waves outside the ST-elevation territory) in STEMI is unclear.
Methods |
A total of 5,733 STEMI patients from 296 clinical centers in 17 countries were classified as (1) silent MI—baseline Q waves outside the infarct-related artery territory and no history of prior MI, (2) history of prior MI (HxMI), or (3) no prior MI.
Results |
Of 5,733 STEMI patients, 419 (7.3%) had silent MI, 693 (12.1%) had HxMI, and 4,621 (80.6%) had no prior MI. Ninety-day death and death/congestive heart failure/shock were higher in patients with HxMI (8.4% and 15.3%, respectively) and silent MI (6.7% and 13.9%, respectively) compared with patients with no prior MI (4.0% and 9.1%, respectively) (P ≤ .001 for all). After baseline adjustment, patients with HxMI were at increased risk for 90-day death (adjusted hazard ratio [HR] 1.62, 95% CI 1.18-2.21), whereas both those with HxMI and those with silent MI had increased risk of 90-day death/congestive heart failure/shock compared with those with no prior MI (adjusted HR 1.54, 95% CI 1.23-1.93 and adjusted HR 1.46, 95% CI 1.10-1.93, respectively).
Conclusions |
Seven percent of STEMI patients had a silent MI. They represent a novel subgroup at increased risk comparable to those with known prior MI. Hence, in future studies, acquiring baseline Q wave data outside the distribution of acute injury should broaden the prognostic insights from STEMI patients with a prior MI.
Le texte complet de cet article est disponible en PDF.Plan
Vol 160 - N° 4
P. 671-677 - octobre 2010 Retour au numéro
Article précédent
- International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences
- Marzia Lotrionte, Giuseppe Biondi-Zoccai, Massimo Imazio, Davide Castagno, Claudio Moretti, Antonio Abbate, Pierfrancesco Agostoni, Antonio L. Brucato, Pietro Di Pasquale, Marja Raatikka, Giuseppe Sangiorgi, Antonio Laudito, Imad Sheiban, Fiorenzo Gaita
- Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial
- Andrea H. Tackett, Alison L. Bailey, Joanne Micale Foody, Julie M. Miller, Carolyn Apperson-Hansen, E. Magnus Ohman, Judith S. Hochman, Sharon L. Karnash, Robert M. Califf, Eric J. Topol, David J. Moliterno
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?